Codis announces three senior business development appointments
pharmafile | June 18, 2026 | Appointment | |Â Â CodisÂ
Codis has announced three strategic appointments within its Business Development function.
Pedro Fernandes Botas has been appointed as Business Development Director, Europe. With a strong commercial background across Lotus Pharmaceutical, Faes Farma, Bene, Labatec Pharma and Hovione, Botas brings deep expertise in building strategic partnerships and opening new market opportunities across the region. His role is focused on expanding Codis’ European presence in spray drying and related particle‑engineering services while supporting the evolution of the company’s commercial approach.
Suzanne Brady has been appointed as Business Development Director, US. Brady brings extensive experience from Hovione, Mikart, Serán Bioscience and Lonza, along with a proven record of driving commercial success and developing strategic alliances. Her remit centres on identifying and developing new business opportunities in the US pharmaceutical spray drying market and contributing to the company’s broader commercial strategy.
Derek Deckrader has been appointed as Business Development Director, US, based in St. Louis. Deckrader brings significant commercial experience from Pharma Tech, Martin Bauer and Sensient, with a strong track record in client engagement and solution development. Unlike the spray-drying-focused roles of Botas and Brady, Deckrader’s responsibilities extend across Codis’ full US portfolio, emphasising aqueous spray drying, microencapsulation and granulation technologies, value-added ingredient solutions for the vitamins, minerals and supplements (VMS) industry, and finished dose manufacturing services that enable end-to-end product development and commercialisation.
Codis is a global contract development and manufacturing organisation (CDMO) specialising in spray drying, amorphous solid dispersions (ASDs) and advanced particle engineering.
